ImaginAb, a clinical-stage developor of in vivo molecular imaging agents based on antibody fragment technology, has entered into a collaboration and commercialization agreement with H. Lundbeck.

Under the terms of the agreement, ImaginAb of Inglewood, Calf., and Lundbeck of Deerfield, Ill., will collaborate on a new central nervous system target to explore the use of re-engineered antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

Under the terms of the agreement, the parties said they will collaborate to concurrently develop biologics with improved BBB transport and imaging agents that are capable of quantitating kinetics. The agreement also includes an option for Lundbeck to commercialize the results of the collaboration for both diagnostic and therapeutic uses.